Aspire Private Capital’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

Aspire Private Capital’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-80	Closed	-$509	–	760
2023 Q4	$509	Hold	80	–	–	﹤0.01%	642
2023 Q3	$344	Hold	80	–	–	﹤0.01%	651
2023 Q2	$206	Hold	80	–	–	﹤0.01%	648
2023 Q1	$546	Hold	80	–	–	﹤0.01%	599
2022 Q4	$570	Hold	80	–	–	﹤0.01%	588
2022 Q3	$1K	Hold	80	–	–	﹤0.01%	600
2022 Q2	$1K	Hold	80	–	–	﹤0.01%	591
2022 Q1	$1K	Buy	+80	New	+$1.48K	﹤0.01%	585

Aspire Private Capital's FRLN Position: Q1 2024 in Review

Aspire Private Capital sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 80 shares — an estimated $509 sold.

Aspire Private Capital first reported a position in FRLN in Q1 2022 and held it in 8 quarters. The position peaked at $1K in Q3 2022. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

Aspire Private Capital reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Aspire Private Capital sold 80 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $509.
Aspire Private Capital first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q1 2022 and held it in 8 quarters.
Aspire Private Capital's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $1K in Q3 2022.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on Aspire Private Capital's 13F filing for Q1 2024, filed 18 Apr 2024.